Skip to Content

Press Releases

Date Title and Summary Additional Formats
Feb 28, 2024
Achieved FY2023 core financial objectives, delivering substantial ongoing reductions in expenses and cash burn while expanding revenue and gross margins Completed merger with SomaLogic, activating strategy to build scaled leader in life sciences tools and services Combined pro forma revenue for
Feb 26, 2024
SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – and Next Gen Diagnostics announce the execution of a long-term agreement aimed at revolutionizing the
Feb 22, 2024
SOUTH SAN FRANCISCO, Calif. , Feb. 22, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that management will participate in the following investor conferences: TD Cowen’s 44th
Feb 14, 2024
SOUTH SAN FRANCISCO, Calif. , Feb. 14, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that it will report fourth quarter and full year 2023 financial results on Wednesday,
Feb 07, 2024
Increasing access to Imaging Mass Cytometry in pharmaceutical and clinical research settings SOUTH SAN FRANCISCO, Calif. , Feb. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today
Jan 08, 2024
Achieving scale with pro forma full year 2023 revenue of approximately $192 million SOUTH SAN FRANCISCO, Calif. , Jan. 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB) ( Standard BioTools or the Company), driven by a bold purpose –  Unleashing tools to accelerate breakthroughs in
Jan 05, 2024
Establishes Leading Platform of Complementary Multi-omic Technologies with Enhanced Scale and Commercial Reach; Strengthened Balance Sheet to Self-Fund Future Growth Initiatives SOUTH SAN FRANCISCO, Calif. , Jan. 05, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc.
Jan 04, 2024
SOUTH SAN FRANCISCO, Calif. , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health , today announced that its stockholders voted to approve all proposals required to be approved in connection
Jan 04, 2024
Stockholder Approval Represents Key Milestone Toward Completion of Standard BioTools Transaction Combination Will Create a Diversified Leader in Life Sciences Tools BOULDER, Colo. , Jan. 4, 2024 /PRNewswire/ -- SomaLogic, Inc. (Nasdaq: SLGC) ("the Company"), a leader in proteomics technology, today
Jan 02, 2024
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Both Recommend SomaLogic Stockholders Vote "FOR" Proposed Merger with Standard BioTools BOULDER, Colo. ,  Jan. 2, 2024  /PRNewswire/ -- SomaLogic, Inc. (Nasdaq:  SLGC ) ("the Company"), a leader in proteomics technology, today sent the